


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sbpgroup.com

(Stock code: 1177)

**SHARE PURCHASE PLAN FOR AN
AGGREGATE AMOUNT OF NOT EXCEEDING HK\$2 BILLION**

This announcement is made by Sino Biopharmaceutical Limited (the “**Company**”) pursuant to the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and Rules 13.09 and 37.47B(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”).

The board of directors (the “**Board**”) of the Company has noted the recent volatility in the price of the shares of the Company and considered the value of the Company is currently grossly underestimated. The Board has decided to repurchase ordinary shares of the Company (“**Shares**”) from the open market in order to boost investors’ confidence and enhance shareholders’ return as soon as possible.

The Board refers to the circular published by the Company on 29 April 2026 (the “**Circular**”) amongst which a Share Buy-Back Mandate (as defined in the Circular) will be put forward for approval by the Company’s shareholders on 17 June 2026, the date of the Company’s annual general meeting (“**AGM**”).

On 12 June 2026, the Board resolved to approve a share purchase plan (the “**Share Purchase Plan**”), pursuant to which the Company will, subject to market conditions, (1) buy back Shares from the open market subject to and pursuant to the Share Buy-Back Mandate granted at the AGM, and (2) under the restricted share award scheme adopted by the Company on 5 January 2018, instruct the trustee responsible for administering the share award scheme to purchase Shares from the open market, for an aggregate consideration of not exceeding HK\$2 billion (the “**Share Purchase Amount**”) over the next 12 months. The Board will review from time to time and determine at its sole discretion how the Share Purchase Amount will be allocated between the buyback of Shares and the purchase of award shares.

Since the beginning of 2026, the Company has also purchased an aggregate of 60,350,000 Shares (including repurchases and instructing the trustee responsible for managing the share award scheme to purchase), for a total consideration of approximately HK\$337,964,000.

The Board considers that the implementation of the Share Purchase Plan is in the best interests of the Company and its shareholders as a whole. The share purchase, in the circumstances, demonstrates the Company's confidence in its business outlook and prospects and will ultimately benefit the Company and create value for its shareholders. The Board is of the view that the Company has sufficient financial resources to implement the Share Purchase Plan and at the same time maintain a healthy financial position.

Securities holders of the Company and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 15 June 2026

As at the date of this announcement, the Board of the Company comprises six executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin and Mr. Tian Zhoushan and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.